Nplate® (romiplostim) – Expanded indication
October 18, 2019 - Amgen announced the FDA approval of Nplate (romiplostim), for the treatment of adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Download PDF
